Altimmune, Inc. (ALT): Price and Financial Metrics

Altimmune, Inc. (ALT): $4.22

0.00 (0.00%)

POWR Rating

Component Grades













Add ALT to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where ALT ranks best; there it ranks ahead of 44.5% of US stocks.
  • ALT's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • ALT ranks lowest in Momentum; there it ranks in the 4th percentile.

ALT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ALT is 0 -- better than only 7.28% of US stocks.
  • The ratio of debt to operating expenses for ALTIMMUNE INC is higher than it is for about just 0.44% of US stocks.
  • As for revenue growth, note that ALT's revenue has grown -101.54% over the past 12 months; that beats the revenue growth of merely 0.53% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ALTIMMUNE INC are SGMO, GRTS, ALPN, PSTX, and ATHX.
  • ALT's SEC filings can be seen here. And to visit ALTIMMUNE INC's official web site, go to

ALT Valuation Summary

  • In comparison to the median Healthcare stock, ALT's price/sales ratio is 66714.89% lower, now standing at -3130.9.
  • Over the past 213 months, ALT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ALT.

Stock Date P/S P/B P/E EV/EBIT
ALT 2023-03-24 -3130.9 1.1 -2.5 -1.2
ALT 2023-03-23 -3036.8 1.1 -2.4 -1.1
ALT 2023-03-22 -3044.1 1.1 -2.4 -1.1
ALT 2023-03-21 -3586.8 1.3 -2.9 -1.6
ALT 2023-03-20 -7913.2 2.9 -6.4 -5.0
ALT 2023-03-17 -7979.4 2.9 -6.4 -5.1

ALT Growth Metrics

    Its 3 year price growth rate is now at 62.74%.
  • The 4 year price growth rate now stands at -98.05%.
  • Its year over year price growth rate is now at -69.82%.
ALT's revenue has moved down $1,708,915 over the prior 67 months.

The table below shows ALT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.319658 -67.24694 -86.94232
2022-06-30 3.475217 -69.97215 -96.93701
2022-03-31 3.60484 -72.19478 -101.6567
2021-12-31 4.410356 -78.23794 -97.09082
2021-09-30 3.445404 -69.68439 -83.82328
2021-06-30 6.225836 -61.41412 -68.08273

ALT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALT has a Quality Grade of D, ranking ahead of 13.22% of graded US stocks.
  • ALT's asset turnover comes in at 0.025 -- ranking 360th of 682 Pharmaceutical Products stocks.
  • OPTN, ENTA, and ELTP are the stocks whose asset turnover ratios are most correlated with ALT.

The table below shows ALT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.025 1 -0.839
2021-03-31 0.032 1 -0.867
2020-12-31 0.052 1 -0.992
2020-09-30 0.058 1 -1.332
2020-06-30 0.062 1 -1.567
2020-03-31 0.089 1 -1.191

ALT Price Target

For more insight on analysts targets of ALT, see our ALT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.86 Average Broker Recommendation 1.36 (Strong Buy)

ALT Stock Price Chart Interactive Chart >

Price chart for ALT

ALT Price/Volume Stats

Current price $4.22 52-week high $23.49
Prev. close $4.22 52-week low $3.83
Day low $4.07 Volume 4,137,000
Day high $4.40 Avg. volume 1,885,348
50-day MA $11.09 Dividend yield N/A
200-day MA $12.50 Market Cap 207.96M

Altimmune, Inc. (ALT) Company Bio

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

ALT Latest News Stream

Event/Time News Detail
Loading, please wait...

ALT Latest Social Stream

Loading social stream, please wait...

View Full ALT Social Stream

Latest ALT News From Around the Web

Below are the latest news stories about ALTIMMUNE INC that investors may wish to consider to help them evaluate ALT as an investment opportunity.

Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. “We are delighted to welcome Catherine to our Board of Directors,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be

Yahoo | March 27, 2023

META Stock Price Prediction: Can Meta Platforms Really Hit $250?

Meta Platforms (META) stock is worth checking on Tuesday as investors react to a new rating and price target for the shares.

William White on InvestorPlace | March 21, 2023

Why Is Altimmune (ALT) Stock Down 67% Today?

Altimmune (ALT) stock is losing value on Tuesday after the company released results from a Phase 2 clinical trial for obesity.

William White on InvestorPlace | March 21, 2023

Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial

MOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis of 160 Subjects) Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24Mean weight loss of 11.9% (placebo-adjusted 11.1%) in subjects weighing 115 kg or less at baseline at 2.4 mg dose at Week 24Approximately 50% of subjects achieved 10% or more weight loss and approximately 20% of subjects achieved 15% or more weight loss at the 1.8 mg and 2.4 mg doses at Week 24Robust reductions in waist circumference, serum lipids a

Yahoo | March 21, 2023

Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic steatohepatitis (NASH) trial expected mid-2023 Webcast to be held today, February 28, 2023, at 8:30 am ET GAITHERSBURG, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “The next twelve-mont

Yahoo | February 28, 2023

Read More 'ALT' Stories Here

ALT Price Returns

1-mo -63.49%
3-mo -74.35%
6-mo -67.11%
1-year -32.15%
3-year 38.82%
5-year -88.18%
YTD -74.35%
2022 79.59%
2021 -18.79%
2020 496.83%
2019 -8.25%
2018 -96.55%

Continue Researching ALT

Here are a few links from around the web to help you further your research on Altimmune Inc's stock as an investment opportunity:

Altimmune Inc (ALT) Stock Price | Nasdaq
Altimmune Inc (ALT) Stock Quote, History and News - Yahoo Finance
Altimmune Inc (ALT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7638 seconds.